12419750

Source:http://linkedlifedata.com/resource/pubmed/id/12419750

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0013089, umls-concept:C0030705, umls-concept:C0045093, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0205390, umls-concept:C2239176
pubmed:issue	11
pubmed:dateCreated	2002-11-6
pubmed:abstractText	We determined the maximum tolerated dose (MTD) and then further evaluated the response rate and safety profile of gemcitabine (Gem) plus doxorubicin (Dox) in chemonaïve patients with advanced hepatocellular carcinoma (HCC).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0923-7534
pubmed:author	pubmed-author:ChenJ SJS, pubmed-author:FungM CMC, pubmed-author:HsiehR KRK, pubmed-author:WangC HCH, pubmed-author:YangT STS
pubmed:issnType	Print
pubmed:volume	13
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1771-8
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12419750-Adult, pubmed-meshheading:12419750-Aged, pubmed-meshheading:12419750-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12419750-Biopsy, Needle, pubmed-meshheading:12419750-Carcinoma, Hepatocellular, pubmed-meshheading:12419750-Deoxycytidine, pubmed-meshheading:12419750-Dose-Response Relationship, Drug, pubmed-meshheading:12419750-Doxorubicin, pubmed-meshheading:12419750-Drug Administration Schedule, pubmed-meshheading:12419750-Female, pubmed-meshheading:12419750-Humans, pubmed-meshheading:12419750-Infusions, Intravenous, pubmed-meshheading:12419750-Liver Neoplasms, pubmed-meshheading:12419750-Male, pubmed-meshheading:12419750-Maximum Tolerated Dose, pubmed-meshheading:12419750-Middle Aged, pubmed-meshheading:12419750-Neoplasm Invasiveness, pubmed-meshheading:12419750-Neoplasm Staging, pubmed-meshheading:12419750-Prognosis, pubmed-meshheading:12419750-Survival Analysis, pubmed-meshheading:12419750-Taiwan, pubmed-meshheading:12419750-Treatment Outcome
pubmed:year	2002
pubmed:articleTitle	Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
pubmed:affiliation	Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II, Clinical Trial, Phase I